Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52.
Smolen JS, Mease P, Tahir H, Schulze-Koops H, de la Torre I, Li L, Hojnik M, Sapin C, Okada M, Caporali R, Gratacós J, Goupille P, Liu Leage S, Pillai S, Nash P. Smolen JS, et al. Among authors: sapin c. Ann Rheum Dis. 2020 Oct;79(10):1310-1319. doi: 10.1136/annrheumdis-2020-217372. Epub 2020 Jul 13. Ann Rheum Dis. 2020. PMID: 32660977 Free PMC article. Clinical Trial.
Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study.
Smolen JS, Sebba A, Ruderman EM, Schulze-Koops H, Sapin C, Gellett AM, Sprabery AT, Li L, de la Torre I, Gallo G, Liu-Leage S, Pillai S, Reis P, Nash P. Smolen JS, et al. Among authors: sapin c. Rheumatol Ther. 2020 Dec;7(4):1021-1035. doi: 10.1007/s40744-020-00250-3. Epub 2020 Nov 16. Rheumatol Ther. 2020. PMID: 33200394 Free PMC article.
Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Psoriatic Arthritis Patients Regardless of Psoriasis Severity: 52-Week Post Hoc Results from SPIRIT-H2H.
Kristensen LE, Okada M, Tillett W, Leage SL, El Baou C, Sapin C, Bradley AJ, Meszaros G, Dutz JP, de Vlam K. Kristensen LE, et al. Among authors: sapin c. Rheumatol Ther. 2022 Feb;9(1):109-125. doi: 10.1007/s40744-021-00388-8. Epub 2021 Oct 28. Rheumatol Ther. 2022. PMID: 34709605 Free PMC article.
Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial.
Reich K, Kristensen LE, Smith SD, Rich P, Sapin C, Leage SL, McKenzie R, Schuster C, Riedl E, Gooderham M. Reich K, et al. Among authors: sapin c. Dermatol Pract Concept. 2022 Apr 1;12(2):e2022104. doi: 10.5826/dpc.1202a104. eCollection 2022 May. Dermatol Pract Concept. 2022. PMID: 35646453 Free PMC article.
130 results